ID
37320
Beschreibung
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form includes Clinical Chemistry and Haematology lab examinations and results and is to be filled in at Screening, on Days 2 and 3 at 0 hrs and Day 3 at 24 hrs (i.e. Day 4 - 0 hrs) and at Follow-Up for all cohorts and for any repeat analyses.
Link
https://clinicaltrials.gov/ct2/show/NCT00996840
Stichworte
Versionen (1)
- 16.07.19 16.07.19 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
16. Juli 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Local Laboratory - Clinical Chemistry and Haematology
- StudyEvent: ODM
Beschreibung
Clinical Chemistry Analysis
Alias
- UMLS CUI-1
- C0008000
- UMLS CUI-2
- C0022885
Beschreibung
Fill in the following items for each analysed feature at all visits (except for repeat assessments). The following items are not mandatory for Days 2 and 3 for all cohorts: 16 = Prothrombin Time (PT) 17 = Partial Thromboplastin Time (PTT) 19 = International normalized ratio (INR) 22 = Arterial Blood pH 23 = Serum Estradiol item 22 = Arterial Blood pH is not mandatory for Follow-up Select the appropriate feature for Repeat Analysis. The inclusion of 23 = Serum Estradiol during Screening and Follow-Up is a change to the study.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C0022885
Beschreibung
Clinical chemistry result type
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C0332307
Beschreibung
if applicable
Datentyp
float
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C2347373
Beschreibung
if applicable
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C2350015
Beschreibung
Haematology Lab Analysis
Alias
- UMLS CUI-1
- C0022885
- UMLS CUI-2
- C0018941
Beschreibung
Select the appropriate feature for Repeat Analysis At all other visits, fill in the following items for each analysed feature.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0022885
- UMLS CUI [1,2]
- C0018941
Beschreibung
Haematology Lab result type
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0022885
- UMLS CUI [1,2]
- C0018941
- UMLS CUI [1,3]
- C1274040
- UMLS CUI [1,4]
- C0332307
Beschreibung
if applicable
Datentyp
float
Alias
- UMLS CUI [1,1]
- C0018941
- UMLS CUI [1,2]
- C2347373
Beschreibung
if applicable
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0018941
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C2350015
Ähnliche Modelle
Local Laboratory - Clinical Chemistry and Haematology
- StudyEvent: ODM
C0022885 (UMLS CUI-2)
C0200345 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C0200345 (UMLS CUI [1,2])
C0022885 (UMLS CUI-2)
C0022885 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347373 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,3])
C0018941 (UMLS CUI-2)
C0018941 (UMLS CUI [1,2])
C0018941 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,4])
C2347373 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,3])
Keine Kommentare